Amphista Therapeutics

Amphista Therapeutics is a Cambridge‑based biopharmaceutical company developing a next‑generation targeted protein degradation (TPD) platform — branded Eclipsys™ and Targeted Glue® — to create small‑molecule degraders for oncology and neurodegenerative diseases.[4][3]

High‑Level Overview

Amphista Therapeutics is a portfolio company spun out to commercialize rationally designed *Targeted Glue®* degraders that aim to remove disease‑causing proteins rather than simply inhibit them, with lead programs focused on oncology targets such as SMARCA2, TEAD and KRAS G12D and neurodegeneration‑relevant targets such as HDAC6.[4][1][3]
The company builds small‑molecule targeted protein degraders using its proprietary Eclipsys™ drug‑development platform to broaden the scope and drug‑like properties of TPD beyond CRBN/VHL‑based approaches, serving biopharma (as an innovator developer and partner) and ultimately patients with cancers and severe neurodegenerative disorders.[4][3][1] Amphista presents its technology as solving limitations of early degrader modalities (e.g., tissue scope, resistance risk and physicochemical liabilities) and has shown commercial traction via partnerships, including a 2022 discovery/collaboration agreement with Bristol Myers Squibb.[3]

Origin Story

Amphista was incorporated in the UK in December 2017 and is headquartered at Granta Park in Cambridge, UK.[5][4] The company was founded out of academic TPD expertise from Professor Alessio Ciulli’s labs at the University of Dundee and was seeded by life‑science investors led by Advent Life Sciences (and supported by Forbion, Gilde Healthcare, Novartis Venture Fund, Eli Lilly & Company and the Dementia Discovery Fund).[3][2] Early pivotal moments include its formation as an Advent spin‑out, successful fundraising (over $60M reported to date) and the multi‑year collaboration and licensing deal with Bristol Myers Squibb that included upfront and milestone payments and milestone achievement announcements since 2022.[3][2]

Core Differentiators

• Proprietary mechanism and platform: Amphista’s *Eclipsys™* platform and *Targeted Glue®* chemistry are positioned as a distinct next‑generation TPD approach intended to engage a broader set of cellular degradation pathways than classical PROTACs and molecular glues.[4][3]
  - Drug‑like design focus: Emphasis on improving physicochemical and tissue‑distribution properties to expand therapeutic reach beyond typical CRBN/VHL‑based degraders.[4][3]
  - Portfolio breadth and validated targets: Programs publicly noted against oncology‑relevant targets (SMARCA2, TEAD, KRAS G12D) and HDAC6 for neurodegeneration, indicating both target diversity and clinical relevance.[1][3]
  - Strategic partnerships and investor backing: Early commercial validation via a multi‑hundred‑million‑dollar potential collaboration with Bristol Myers Squibb and backing from leading life‑science investors, which supports R&D scale‑up and de‑risking.[3][2]

Role in the Broader Tech/Life‑Sciences Landscape

Amphista is riding the broader industry trend toward targeted protein degradation as a modality to drug previously intractable targets and to produce more durable functional knockdown of pathogenic proteins, an area attracting heavy academic and venture investment since the late 2010s.[4][3] The company’s timing matters because limitations in first‑generation degraders (ligase dependence, physicochemical constraints, resistance mechanisms) have motivated demand for alternative chemistries that can reach new tissues and targets — a gap Amphista explicitly targets with its Targeted Glue® approach.[4][3] By partnering with major pharmas and focusing on genetically/clinically validated targets, Amphista both accelerates translational routes for TPD science and influences the ecosystem by demonstrating business models for advanced degrader platforms (academic spin‑out → VC syndicate → pharma collaboration).[3][2]

Quick Take & Future Outlook

Amphista’s near‑term path centers on advancing discovery programs through preclinical development, maturing BMS and other collaborations and moving select programs toward IND‑enabling studies — progress that will be critical to validate the claimed advantages of Eclipsys™ in vivo and across target classes.[3][4] Key trends that will shape Amphista’s trajectory include competitive advances in degrader chemistries, clinical readouts from peer TPD programs that set safety/efficacy benchmarks, and continued pharma partnering appetite for platform technologies that de‑risk R&D. If Amphista’s Targeted Glue® molecules demonstrate superior drug‑like properties and broader tissue reach in nonclinical and early clinical assessments, the company could become a leading technology provider in next‑generation TPD and a go‑to partner for tackling oncology and neurodegeneration targets otherwise difficult to drug.[4][3]

If you’d like, I can:
- Summarize Amphista’s public pipeline and partnership timelines into a one‑page slide, or
- Pull and annotate the company’s press releases and investor pages to build a chronology of milestones and financings.